Introduction:

Melanoma is a public health problem, it represents 4% of malignant skin tumors and is responsible for 80% of deaths from this type of neoplasm.

Objective

: To present the response to Temozolomide in patients with metastatic melanoma.

Methods:

Descriptive and cross-sectional study. The clinical response of patients with metastatic melanoma, managed with Temozolomide 200 mg/m2 once a day, for five days every 28 days, was analyzed. The risk factors analyzed were: histological variety, topographic region of the primary lesion, metastasis, ulceration and Breslow. Descriptive statistics were used, for normality Kolmogorov-Smirnoff, Student's t-test, as well as binary logistic regression.

Results:

There were 51 files, 47 met the criteria; 25 men, 22 women, mean age 54.5, minimum 22, maximum 85 years. Complete response was obtained in 3(6%), partial response in 7(14.8%), stable disease in 10(21%) and disease progression in 27(57.4%) patients. The presence of ulceration is associated with a higher Breslow index, and as a result, a higher risk of disease progression.

Conclusions:

Temozolomide as monotherapy is a treatment that presents low rates of complete response and partial response, showing better results in patients with lymph node metastases.

        · abstract in Spanish     · text in English | Spanish     · English ( pdf ) | Spanish ( pdf )